JP2016535781A5 - - Google Patents

Download PDF

Info

Publication number
JP2016535781A5
JP2016535781A5 JP2016552446A JP2016552446A JP2016535781A5 JP 2016535781 A5 JP2016535781 A5 JP 2016535781A5 JP 2016552446 A JP2016552446 A JP 2016552446A JP 2016552446 A JP2016552446 A JP 2016552446A JP 2016535781 A5 JP2016535781 A5 JP 2016535781A5
Authority
JP
Japan
Prior art keywords
component
composition
composition according
ionic liquid
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2016552446A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016535781A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/063745 external-priority patent/WO2015066647A2/en
Publication of JP2016535781A publication Critical patent/JP2016535781A/ja
Publication of JP2016535781A5 publication Critical patent/JP2016535781A5/ja
Withdrawn legal-status Critical Current

Links

JP2016552446A 2013-11-03 2014-11-03 経皮薬物送達のためのイオン性液体 Withdrawn JP2016535781A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361899294P 2013-11-03 2013-11-03
US61/899,294 2013-11-03
PCT/US2014/063745 WO2015066647A2 (en) 2013-11-03 2014-11-03 Ionic liquids for transdermal drug delivery

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019030302A Division JP6674058B2 (ja) 2013-11-03 2019-02-22 経皮薬物送達のためのイオン性液体

Publications (2)

Publication Number Publication Date
JP2016535781A JP2016535781A (ja) 2016-11-17
JP2016535781A5 true JP2016535781A5 (enExample) 2017-12-07

Family

ID=53005413

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016552446A Withdrawn JP2016535781A (ja) 2013-11-03 2014-11-03 経皮薬物送達のためのイオン性液体
JP2019030302A Active JP6674058B2 (ja) 2013-11-03 2019-02-22 経皮薬物送達のためのイオン性液体
JP2020037741A Withdrawn JP2020097633A (ja) 2013-11-03 2020-03-05 経皮薬物送達のためのイオン性液体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019030302A Active JP6674058B2 (ja) 2013-11-03 2019-02-22 経皮薬物送達のためのイオン性液体
JP2020037741A Withdrawn JP2020097633A (ja) 2013-11-03 2020-03-05 経皮薬物送達のためのイオン性液体

Country Status (7)

Country Link
US (3) US10449254B2 (enExample)
EP (1) EP3062819B1 (enExample)
JP (3) JP2016535781A (enExample)
KR (1) KR102286115B1 (enExample)
CA (2) CA3100536A1 (enExample)
ES (1) ES2908345T3 (enExample)
WO (1) WO2015066647A2 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8513305B2 (en) 2007-05-14 2013-08-20 Research Foundation Of State University Of New York Induction of a physiological dispersion response in bacterial cells in a biofilm
EP3395368A1 (en) * 2014-10-30 2018-10-31 Asahi Kasei Kabushiki Kaisha Transdermal absorption enhancer and transdermal absorption enhancement aid
CA2931913C (en) 2015-06-12 2024-03-19 Kemira Oyj Bitumen separation using ionic liquids comprising unsubstituted or substituted primary, secondary or tertiary amines, pyridines, amidines, guanidines and fatty acids and/or resin acids
CA3035414C (en) 2016-08-29 2022-02-22 The Regents Of The University Of California Topical formulations based on ionic species for skin treatment
US11274137B1 (en) * 2016-10-04 2022-03-15 United States Of America As Represented By The Secretary Of The Air Force Ultra-stable protein ionic liquids
US10828265B2 (en) 2016-12-09 2020-11-10 The Regents Of The University Of California Formulations of propranolol and analogs as an amorphous melt or ionic liquid for transdermal drug delivery
WO2018222924A1 (en) * 2017-06-01 2018-12-06 Arizona Board Of Regents On Behalf Of Northern Arizona University Antibiofilm formulations
WO2019099837A1 (en) * 2017-11-17 2019-05-23 President And Fellows Of Harvard College Ionic liquids for internal delivery
JP2019131480A (ja) * 2018-01-29 2019-08-08 旭化成株式会社 経皮吸収促進剤及び経皮製剤
WO2019183142A1 (en) * 2018-03-19 2019-09-26 Cage Bio Inc. Ionic liquid compositions for treatment of rosacea
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
KR101959524B1 (ko) * 2018-09-19 2019-03-18 주식회사 우신라보타치 리도카인을 포함한 이온토포레시스용 점착성 카타플라스마 시스템
EP3930757A1 (en) 2019-03-01 2022-01-05 President And Fellows Of Harvard College Methods and compositions for protein delivery
US20220257767A1 (en) * 2019-04-03 2022-08-18 President And Fellows Of Harvard College Ionic liquids for drug delivery
ES2912262T3 (es) * 2019-05-29 2022-05-25 Hopitaux Paris Assist Publique Sistema eutéctico de las catequinas del té verde
AU2020378151A1 (en) * 2019-11-08 2022-05-26 Cage Bio, Inc. Topical delivery of tofacitinib using ionic liquid
WO2021102084A1 (en) 2019-11-22 2021-05-27 President And Fellows Of Harvard College Ionic liquids for drug delivery
WO2021119198A1 (en) * 2019-12-09 2021-06-17 Cage Bio, Inc. Topical delivery of rna interference agents using ionic liquid
US11684594B2 (en) 2020-05-12 2023-06-27 President And Fellows Of Harvard College Antifungal prophylaxis for cornea
US20230329988A1 (en) * 2020-06-26 2023-10-19 Cage Bio Inc. Sanitizing compositions containing ionic liquid
US20230372273A1 (en) * 2020-10-05 2023-11-23 Cage Bio, Inc. Ionic liquid compositions for skin diseases and conditions
ES3049508T3 (en) * 2020-10-29 2025-12-17 Hisamitsu Pharmaceutical Co Ropinirole-containing patch and method for improving skin permeability of ropinirole
EP4243952A1 (en) * 2020-11-13 2023-09-20 Universidade do Minho Eutectic compositions, methods and uses thereof
WO2022256291A1 (en) 2021-06-01 2022-12-08 President And Fellows Of Harvard College Hydrogel devices for drug delivery to the ear
WO2022271537A1 (en) 2021-06-25 2022-12-29 President And Fellows Of Harvard College Compositions and methods relating to injectable microemulsions
US12005134B2 (en) 2021-06-30 2024-06-11 Abe Pharmaceutical Composition for stimulating facial hair growth and methods of manufacturing a composition for stimulating facial hair growth
IL311885A (en) 2021-10-08 2024-06-01 Harvard College Ionic liquids for drug delivery
CA3237751A1 (en) 2021-11-10 2023-05-19 Tyler Brown Ionic liquid compositions
CN116474153B (zh) * 2022-01-17 2024-09-27 四川大学 一种基于竹纤维-低共熔溶剂-明胶的皮肤溃疡护理贴膜
US12109303B2 (en) 2022-04-18 2024-10-08 ISHA Therapeutics LLC Orally dissolving antimicrobial film compositions and methods of their use
CN115671285B (zh) * 2022-08-24 2024-01-05 上海市皮肤病医院 一种抗真菌溶液及其制备方法和应用
WO2025147130A1 (ko) * 2024-01-03 2025-07-10 주식회사 바이온리퀴드 이온성 액체 또는 공융 용매를 이용한 신규 약물제형
WO2026041873A1 (en) * 2024-08-21 2026-02-26 The University Of Reading Compositions for systemic administration

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3342840A (en) * 1964-03-23 1967-09-19 Shell Oil Co Cationic ester production
US4042327A (en) 1976-01-15 1977-08-16 Waters Associates, Inc. Ion-pairing chromatography
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
JPS62209523A (ja) 1986-03-11 1987-09-14 Fuji Photo Film Co Ltd 感光材料
US4892737A (en) * 1988-09-22 1990-01-09 University Of Florida Composition and method for enhancing permeability of topical drugs
HU203372B (en) 1989-02-24 1991-07-29 Richter Gedeon Vegyeszet Process for producing hyaluronic associates and pharmaceutical compositions and cosmetics comprising such active ingredient
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5356802A (en) 1992-04-03 1994-10-18 The Johns Hopkins University Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease
US5487994A (en) 1992-04-03 1996-01-30 The Johns Hopkins University Insertion and deletion mutants of FokI restriction endonuclease
US5527675A (en) 1993-08-20 1996-06-18 Millipore Corporation Method for degradation and sequencing of polymers which sequentially eliminate terminal residues
DE4331012A1 (de) 1993-09-13 1995-03-16 Bayer Ag Nukleinsäuren-bindende Oligomere mit N-Verzweigung für Therapie und Diagnostik
US5674908A (en) 1993-12-20 1997-10-07 Life Technologies, Inc. Highly packed polycationic ammonium, sulfonium and phosphonium lipids
MX9604411A (es) * 1994-03-28 1997-12-31 Univ Columbia Composicion para inactivar irritantes en fluidos.
JP4236281B2 (ja) 1995-06-07 2009-03-11 ジェン−プローブ・インコーポレーテッド ミセル保護アッセイ
US5786571A (en) 1997-05-09 1998-07-28 Lexmark International, Inc. Wrapped temperature sensing assembly
ES2298438T3 (es) * 2001-12-21 2008-05-16 Rhodia Inc. Composiciones estables combinadas de tensioactivos cationicos y anionicos.
US7102000B2 (en) * 2002-03-08 2006-09-05 Incyte San Diego Inc. Heterocyclic amide derivatives for the treatment of diabetes and other diseases
US6858217B2 (en) * 2002-03-22 2005-02-22 Unilever Home & Personal Care Usa Division Of Conopco, Inc. Stabilization of terpenoids in cosmetic compositions
DE602005010812D1 (de) 2004-11-22 2008-12-18 Hisamitsu Pharmaceutical Co Transdermales Pflaster enthaltend einen schmelzpunktsenkenden Hilfsstoff
US9139850B2 (en) 2005-05-19 2015-09-22 L'oreal Vectorization of dsRNA by cationic particles and topical use
EP2016056A4 (en) 2006-04-21 2010-11-10 Univ Boston IONIC VISCOELASTIC AND VISCOELASTIC SALTS
WO2008031105A1 (en) 2006-09-08 2008-03-13 Delaval Holdings Ab Polymeric guanidine salt-based germicides
JP5117732B2 (ja) 2007-01-29 2013-01-16 株式会社 メドレックス 外用剤用の低刺激性溶解助剤
JP4952272B2 (ja) 2007-01-29 2012-06-13 株式会社ツムラ (z)−リグスチリドの製造方法
US8247198B2 (en) 2007-09-21 2012-08-21 Friedrich Srienc Enzymatic processing in deep eutectic solvents
WO2009066457A1 (ja) * 2007-11-22 2009-05-28 Medrx Co., Ltd. 脂肪酸系イオン液体を有効成分とする外用剤組成物
US8022014B2 (en) 2008-03-26 2011-09-20 Shrieve Chemical Products, Inc. Deep eutectic solvents and applications
WO2010109544A1 (ja) 2009-03-27 2010-09-30 株式会社メドレックス 核酸を有効成分とする外用剤組成物
WO2011056545A2 (en) * 2009-10-26 2011-05-12 Trustees Of Boston University Antimicrobial ionic liquids
WO2011057209A1 (en) 2009-11-06 2011-05-12 Qlt, Inc. Acidic ophthalmic formulations
NO2510096T3 (enExample) 2009-12-10 2015-03-21
JP6148676B2 (ja) 2011-11-04 2017-06-14 リポテック, エセ.ア. 活性化受容体を阻害するペプチド、および化粧品組成物または薬学的組成物におけるそれらの使用
EP2597099B1 (en) 2011-11-23 2018-08-15 King Saud University Deep eutectic solvent and method for its preparation
EP2740484A1 (en) 2012-12-05 2014-06-11 Lipotec, S.A. Compounds useful in the treatment and/or care of the skin, hair and/or muccous membranes and their cosmetic or pharmaceutical compositions
FR3002452B1 (fr) 2013-02-28 2016-02-12 Dermaconcept Jmc Composition dermatologique antimicrobienne topique
CN105434337B (zh) 2015-04-03 2019-08-16 武汉科福新药有限责任公司 盐酸普萘洛尔亚微乳凝胶及其制备方法和用途

Similar Documents

Publication Publication Date Title
JP2019073561A5 (enExample)
US12134628B2 (en) Antimicrobial organosilanes
JP6267218B2 (ja) 揮発性、疎水性溶媒を用いた生物学的に活性な薬剤の送達
PH12017502092A1 (en) Topical pharmaceutical compositions
NZ711225A (en) A pharmaceutical formulation comprising omecamtiv mecarbil, processess and uses
AU2019219767A1 (en) Treatments for resistant acne
WO2018191450A3 (en) GENE THERAPY FOR A DEFICIENCY IN AADC
MX2018004376A (es) Formulaciones inyectables de neuroesteroides que contienen nanoparticulas.
WO2015066647A3 (en) Ionic liquids for transdermal drug delivery
MX2019013701A (es) Metodos para mejorar suministro de farmacos y efectividad de agentes terapeuticos.
MY199903A (en) Combination therapy with controlled-release cnp agonists
JP2018512454A5 (enExample)
KR20120022930A (ko) 은 설파디아진 및 키토산을 사용하여 제조한 약용 크림 및 이의 제조 방법
JP2016540785A5 (enExample)
EP4552650A3 (en) Methods and compositions for treatment of skin
MX2016009063A (es) Preparacion farmaceutica que contiene compuesto de acido piridilaminoacetico.
RU2014150505A (ru) Способ идентификации лигандов рецептора ahr, которые обладают терапевтической себосупрессивной активностью, и указанные лиганды
JP2018509388A5 (enExample)
MX395613B (es) COMPOSICIONES DE ZINC-y-PGA Y MÉTODOS PARA TRATAR EL CANCER.
MX2023009600A (es) Análogos de la oxa-ibogaína para el tratamiento de trastornos por consumo de sustancias.
AR109012A1 (es) Sistema de administración transdérmica que contiene galantamina o sales de esta
EP4234021A3 (en) Pharmaceutical composition comprising an adenosine derivative for use in the prevention or treatment of diabetic nephropathy
NZ703176A (en) Stable pexiganan formulation
JP2020519656A5 (enExample)
CN103127544A (zh) 含银壳聚糖敷料及其制备方法和用途